Although no data is available on the envelope glycoprotein (gp120) of the multi-epitope peptide vaccine, it can trigger both the cellular and humoral immune response, which can help develop a vaccine to reduce the complete infection in the host. This evidence concerns the gene ERVW-1 and infection.